Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95708 | 0.85 | ERN1 (0.50) | ERN1NFE2L2MEN1KMT2ATDP1 | |
| SCHEMBL1478239 | 0.85 | ERN1 (0.48) | ERN1NFE2L2MEN1KMT2ATDP1 | |
| SCHEMBL8702525 | 0.85 | ERN1 (0.53) | ERN1NFE2L2MEN1KMT2ATDP1 | |
| SCHEMBL1990145 | 0.85 | ERN1 (0.53) | ERN1NFE2L2MEN1KMT2ATDP1 | |
| SCHEMBL547829 | 0.82 | KMT2A (0.61) | ERN1MEN1KMT2ATDP1LMNA | |
| SCHEMBL3679599 | 0.81 | ERN1 (0.50) | ERN1NFE2L2MEN1KMT2ATDP1 | |
| SCHEMBL154794 | 0.78 | ERN1 (0.61) | ERN1NFE2L2MEN1KMT2ATDP1 | |
| SCHEMBL9658857 | 0.77 | KMT2A (0.55) | ERN1MEN1KMT2ATDP1LMNA | |
| SCHEMBL20465749 | 0.77 | — | — | |
| SCHEMBL29540911 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101193843-B | Production process of nucleus-halogenated methylbenzyl alcohol | SHOWA DENKO KK | 2011-05-04 | — | — | CN | claimed |
| CN-101193843-A | Production process of nucleus-halogenated methylbenzyl alcohol | SHOWA DENKO KK (JP) | 2008-06-04 | — | — | CN | claimed |
| US-20240400575-A1 | POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | UNIV BARCELONA (ES) | 2024-12-05 | — | — | US | disclosed |
| US-11884714-B2 | Cyclic peptide analogs of melanocortin and amanitin and methods of making such | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-01-30 | — | — | US | disclosed |
| EP-3810572-B1 | POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | UNIV BARCELONA (ES) | 2023-11-15 | — | — | EP | disclosed |
| US-11542397-B2 | Liquid composition, quantum dot-containing film, optical film, light-emitting display element panel, and light-emitting display device | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20220298219-A1 | CYCLIC PEPTIDE ANALOGS OF MELANOCORTIN AND AMANITIN AND METHODS OF MAKING SUCH | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-09-22 | — | — | US | disclosed |
| US-11396535-B2 | Cyclic peptide analogs of melanocortin and amanitin and methods of making such | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-07-26 | — | — | US | disclosed |
| US-20210309866-A1 | LIQUID COMPOSITION, QUANTUM DOT-CONTAINING FILM, OPTICAL FILM, LIGHT-EMITTING DISPLAY ELEMENT PANEL, AND LIGHT-EMITTING DISPLAY DEVICE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2021-10-07 | — | — | US | disclosed |
| CN-112888674-A | Polycyclic compounds as soluble epoxide hydrolase inhibitors | 巴塞罗那大学 | 2021-06-01 | — | — | CN | disclosed |
| EP-3812805-A1 | LIQUID COMPOSITION, QUANTUM DOT-CONTAINING FILM, OPTICAL FILM, LUMINESCENT DISPLAY ELEMENT PANEL, AND LUMINESCENT DISPLAY DEVICE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2021-04-28 | — | — | EP | disclosed |
| CN-1255864-A | Combination of ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors | SEARLE & CO (US) | 2000-06-07 | — | — | CN | disclosed |
| EP-0971744-A2 | COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-19 | — | — | EP | disclosed |
| US-5994391-A | HYPERLIPEMIC AGENTS; ANTICHOLESTEROL AGENTS | G.D. SEARLE AND COMPANY (US) | 1999-11-30 | — | — | US | disclosed |
| US-5985913-A | GENE EXPRESSION AND CELL GROWTH FACTORS FOR BIOSYNTHESIS | OSI PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| CN-1221414-A | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | SEARLE & CO (US) | 1999-06-30 | — | — | CN | disclosed |
| EP-0888333-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | G.D. Searle & Co. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1998040375-A2 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-17 | — | — | WO | disclosed |
| WO-1997033882-A9 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | — | 1998-02-26 | — | — | WO | disclosed |
| WO-1997033882-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | G.D. SEARLE AND CO. (US) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396535-B2 | Cyclic peptide analogs of melanocortin and amanitin and methods of making such | MC3R, MC5R, MC4R | ERN1 4597/4885NFE2L2 4670/4885MEN1 83/4885 |
| US-11884714-B2 | Cyclic peptide analogs of melanocortin and amanitin and methods of making such | MC3R, MC5R, MC4R | ERN1 4597/4885NFE2L2 4670/4885MEN1 83/4885 |
| US-20220298219-A1 | CYCLIC PEPTIDE ANALOGS OF MELANOCORTIN AND AMANITIN AND METHODS OF MAKING SUCH | MC3R, MC5R, MC4R | ERN1 4597/4885NFE2L2 4670/4885MEN1 83/4885 |
| US-20240400575-A1 | POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | ERN1 1004/4885NFE2L2 475/4885MEN1 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.